<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03810742</url>
  </required_header>
  <id_info>
    <org_study_id>PEP0210</org_study_id>
    <nct_id>NCT03810742</nct_id>
  </id_info>
  <brief_title>Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors</brief_title>
  <official_title>Phase 1 Study of Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaEngine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaEngine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to explore the combination of nal-IRI and TAS-102, which is expected to be an
      effective regimen that could be applied to various cancers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives

        -  to determine the maximum tolerated dose (MTD) of nal-IRI (ONIVYDE®) in combination with
           TAS-102 (LONSURF®)

        -  to evaluate the toxicity profile of the combination therapy Secondary Objectives

        -  to evaluate the preliminary efficacy of the combination therapy of nal-IRI (ONIVYDE®)
           and TAS-102 (LONSURF®)

        -  to study the pharmacokinetics of the combination therapy

      A phase 1 study with a classical 3 + 3 dose escalation design. The target population is
      patients who have pathologically confirmed malignant solid tumors with no standard treatment
      available.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of Dose Limiting Toxicities (DLT)</measure>
    <time_frame>12 months</time_frame>
    <description>to find the Dose Limiting Toxicity (DLT) of nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of Safety profile of nal-IRI and TAS-102 - Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events [Safety] of nal-IRI (ONIVYDE®) in combination with TAS-102 (LONSURF®) according to NCI-CTCAE version 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of objective tumor response as per Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>24 months</time_frame>
    <description>the objective tumor rate by using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics study - (Cmax)</measure>
    <time_frame>6 months</time_frame>
    <description>Concentration of Peak Plasma (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics study - (Tmax)</measure>
    <time_frame>6 months</time_frame>
    <description>maximum concentration of the time taken to reach the (Tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics study - (T1/2)</measure>
    <time_frame>6 months</time_frame>
    <description>time of C max to drop in half taken (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics study - (AUC0→t)</measure>
    <time_frame>6 months</time_frame>
    <description>area of the plasma concentration versus time curve (AUC0→t).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics study - (AUC0→∞)</measure>
    <time_frame>6 months</time_frame>
    <description>area of the plasma concentration versus under curve (AUC0→∞)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics study - (CL)</measure>
    <time_frame>6 months</time_frame>
    <description>rate of clearance (CL)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Refractory Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Nanoliposomal Irinotecan + TAS-102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>different dosage combination by Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanoliposomal Irinotecan</intervention_name>
    <description>Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)</description>
    <arm_group_label>Nanoliposomal Irinotecan + TAS-102</arm_group_label>
    <other_name>TAS-102</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages between 20 to 70 years old

          2. Histologically or cytologically confirmed malignant solid tumors which are advanced or
             metastatic, have failed standard treatment or have no standard treatment currently
             available

          3. ECOG performance status 0 or 1

          4. Normal ECG or ECG without any clinically significant findings

          5. Adequate hematologic parameters, and hepatic and renal function i. White blood cell
             (WBC) count 3000/μL and absolute neutrophil count (ANC) 1500/μL ii. Platelet counts
             100,000/μL without platelet transfusion within 14 days iii. Hemoglobin level 10 g/dL
             iv. Serum total bilirubin- within normal range v. Serum albumin 3.0 g/dL vi. Serum
             alanine aminotransferase (ALT) 3 x the upper limit of normal (ULN) vii. Serum
             creatinine 1.5 x ULN

        Exclusion Criteria:

          1. Received prior nal-IRI (ONIVYDE®) or TAS-102 (LONSURF®) therapy

          2. Known hypersensitivity to any of the components of nal-IRI, other liposomal products,
             fluoropyrimidines or leucovorin

          3. Have liver cirrhosis with Child-Pugh B or Child-Pugh C

          4. With active CNS metastasis (indicated by clinical symptoms, cerebral edema, steroid
             requirement, or progressive growth)

          5. With clinically significant gastrointestinal disorder including hepatic disorders,
             bleeding, inflammation, occlusion, or diarrhea &gt; grade 1

          6. Life expectancy of less than 3 months

          7. Use any anti-cancer or investigational product within 14 days prior to the first date
             of study dosing

          8. History of any second malignancy in the latest 5 years except curatively treated
             non-melanoma skin cancer or treated cervical carcinoma in situ

          9. Uncontrolled inter-current illness including, but not limited to, ongoing or active
             infection requiring antibiotic treatment, symptomatic congestive heart failure,
             unstable angina pectoris, or cardiac arrhythmia, and psychiatric illness or social
             situation that would preclude study compliance

         10. Homozygous for the UGT1A1 28 allele (TA7/TA7), homozygous for UGT1A1 6 allele (A/A),
             or double heterozygous for both UGT1A1 28 allele (TA6/TA7) and UGT1A1 6 allele (G/A)
             (only for dose-finding phase)

         11. Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chia-Chi Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erica Wang</last_name>
    <phone>+886 2 2515-8228</phone>
    <phone_ext>201</phone_ext>
    <email>erica.wang@pharmaengine.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Lin</last_name>
    <phone>+886 2 2515-8228</phone>
    <phone_ext>203</phone_ext>
    <email>erica.wang@pharmaengine.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li-Yuan Bai, MD</last_name>
    </contact>
    <investigator>
      <last_name>Li-Yuan Bai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nai-Jung Chiang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nai-Jung Chiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 21, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2019</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

